In particular, we demonstrate that treatment of the ALKRES-expressing resistant melanoma cells with siRNA or ALK inhibitors in combination with either BRAF or MEK inhibitors, leads to efficient cell growth suppression and apoptosis, suggesting this combination to be an interesting clinical option for patients harbouring both BRAFV600E and expressing ALKRES, especially as more specific ALK inhibitors become available. This evidence concerns the gene MAP2K7 and melanoma.